Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
JSJasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. (JSPR)

NASDAQ · Currency in USD
$0.51 ▲ +0.01 (+2.91%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.52 ▲ +0.01 (+1.96%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$0.50
Open
$0.49
Day's Range
$0.48 – $0.54
52 Week Range
$0.32 – $2.52
Volume
323,719
Avg. Volume
1,108,688
Market Cap
$16.97M
Beta (5Y Monthly)
3.17
PE Ratio (TTM)
--
EPS (TTM)
-$1.11
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.50

Profile: Jasper Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
22
CEO
Jeetinder Singh Mahal

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.06 · Revenue est. $6.00M
DateEst.Actual
Aug 14, 2026-$0.27-$0.10Beat
May 14, 2026-$0.46-$0.04Beat
Mar 30, 2026-$0.79-$0.32Beat
Nov 10, 2025-$1.01-$1.13Miss
Aug 13, 2025-$1.20-$1.74Miss
May 12, 2025-$1.17-$1.41Miss

Analyst view

Consensus price target
$2.50 ▲ +390.2%
Range $2.00 – $3.00
Rating: Buy
Buy 62% · Hold 38% · Sell -0%

Get free alerts on JSPR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.